-
公开(公告)号：KR1020130055431A
公开(公告)日：2013-05-28
申请号：KR1020110121176
申请日：2011-11-18
Applicant: 한국식품연구원
Abstract: PURPOSE: A composition containing a Kalopanax pictus shoot extract for hTRPA1(human Transient Receptor Potential A1) actiation is provided to screen a irritation flavoring agent, a lachrymatory agent, an obesity inhibitor, and hTRPA1 antagonist, and to reduce side effects. CONSTITUTION: A composition for hTRPA1 activation contains a Kalopanax pictus shoot extract or a fraction thereof as an active ingredient. A method for screening an hTRPA1 antagonist comprises: a step of treating hTRPA1 with the extract or the fraction and a candidate substance; and a step of measuring hTRPA1 activation. A candidate is determined as an antagonist to hTRPA1 when the hTRPA1 activation level is lower than a control group. A method for hTRPA1 activation comprises a step of treating a cell with the extract or the fraction.
Abstract translation: 目的：提供含有用于hTRPA1（人类瞬时受体电位A1）作用的Kalopanax pictus芽提取物的组合物以筛选刺激调味剂，泪液剂，肥胖症抑制剂和hTRPA1拮抗剂，并减少副作用。 构成：用于hTRPA1激活的组合物含有作为活性成分的卡拉帕纳克斯提取物或其一部分。 筛选hTRPA1拮抗剂的方法包括：用提取物或级分和候选物质处理hTRPA1的步骤; 和测量hTRPA1激活的步骤。 当hTRPA1激活水平低于对照组时，候选物被确定为hTRPA1的拮抗剂。 hTRPA1激活的方法包括用提取物或级分处理细胞的步骤。
-
公开(公告)号：KR1020130055414A
公开(公告)日：2013-05-28
申请号：KR1020110121155
申请日：2011-11-18
Applicant: 한국식품연구원
IPC: A61K31/216 , A61K31/222 , A61K31/231 , A61P3/04
Abstract: PURPOSE: A composition containing coniferyl alcohol for hTRPA1(human Transient Receptor Potential A1) activation is provided to screen a flavoring agent, a lachrymatory agent, a diabetes or obesity inhibitor, and hTRPA1 antagonist, and to be used as a natural compound without side effects. CONSTITUTION: A composition for hTRPA1 activation contains coniferyl alcohol as an active ingredient. A Kalopanax pictus shoot extract of a Kalopanax pictus shoot fraction contains the compound. A method for screening an antagonist to hTRPA1 comprises: a step of treating hTRPA1 with coniferyl alcohol and a candidate material to be analyzed; a step of measuring hTRPA1 activation; and a step of determining the candidate material as an antagonist when the hTRPA1 activation is lower than a control group. A method for hTRPA1 activation comprises a step of treating a cell with coniferyl alcohol.
Abstract translation: 目的：提供一种含有hTRPA1（人类瞬时受体电位A1）激活的针叶树醇的组合物，用于筛选调味剂，泪液剂，糖尿病或肥胖症抑制剂和hTRPA1拮抗剂，并用作无副作用的天然化合物 。 构成：用于hTRPA1活化的组合物含有针叶树醇作为活性成分。 Kalopanax pictus芽部分的Kalopanax pictus shoot提取物含有该化合物。 用于筛选hTRPA1的拮抗剂的方法包括：用针叶树醇处理hTRPA1和待分析的候选物质的步骤; 测量hTRPA1激活的一个步骤; 以及当hTRPA1激活低于对照组时将候选物质确定为拮抗剂的步骤。 一种hTRPA1激活的方法包括用针叶树醇处理细胞的步骤。
-
公开(公告)号：KR1020130003569A
公开(公告)日：2013-01-09
申请号：KR1020110064994
申请日：2011-06-30
Applicant: 한국식품연구원
CPC classification number: A23L33/105 , A23V2002/00 , A23V2250/21 , A61K36/71
Abstract: PURPOSE: A composition treating lipid metabolism disease, menopausal disease, or cardiovascular disease is provided by comprising a Cimicifuga davurica extract, a Cimicifuga japonica extract, and a Cimicifuga simplex extract. CONSTITUTION: A composition treating lipid metabolism disease, menopausal disease, or cardiovascular disease comprises at least one extract selected from a Cimicifuga heracleifolia extract, a Cimicifuga davurica extract, a Cimicifuga japonica extract, and a Cimicifuga simplex extract as an active ingredient. The active ingredient is the Cimicifuga heracleifolia extract. The lipid metabolism disease is obesity, hyperlipidemia, or fatty liver. The cardiovascular disease is hypertension, angina pectoris, a cut coronary syndrome, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, congestive heart failure, congenital heart disease, coronary artery disease, dyslipoproteinemia, vascular endothelial cell dysfunction, intermittent claudication, ischemia-reperfusion injury, ischemic heart disease, myocardial infarction, peripheral vascular disease, restenosis, atherosclerosis of renal artery, or thrombosis.
Abstract translation: 目的：通过包括Cimicifuga davurica提取物，Cimicifuga japonica提取物和Cimicifuga单克隆提取物来提供治疗脂质代谢疾病，绝经疾病或心血管疾病的组合物。 构成：治疗脂质代谢疾病，绝经疾病或心血管疾病的组合物含有选自Cimicifuga heracleifolia提取物，Cimicifuga davurica提取物，Cimicifuga japonica提取物和Cimicifuga simplex提取物中的至少一种提取物作为活性成分。 活性成分是Cimicifuga heracleifolia提取物。 脂质代谢疾病是肥胖，高脂血症或脂肪肝。 心血管疾病是高血压，心绞痛，冠状动脉综合征，动脉硬化，动脉粥样硬化，颈动脉粥样硬化，脑血管病，充血性心力衰竭，先天性心脏病，冠状动脉疾病，血脂异常，血管内皮细胞功能障碍，间歇性跛行，缺血再灌注损伤 ，缺血性心脏病，心肌梗死，外周血管疾病，再狭窄，肾动脉粥样硬化或血栓形成。
-
-
-
Search Results
64
records
(took 0.019 seconds)
